# Tango Therapeutics, Inc. (TNGX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Tango Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TNGX/mda/fy2025/): filed 2026-03-05; accession 0001193125-26-092518 (https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/TNGX/mda/fy2024/): filed 2025-02-27; accession 0000950170-25-028353 (https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm)
- [FY 2023 MD&A](/company/TNGX/mda/fy2023/): filed 2024-03-18; accession 0000950170-24-032516 (https://www.sec.gov/Archives/edgar/data/1819133/000095017024032516/tngx-20231231.htm)
- [FY 2022 MD&A](/company/TNGX/mda/fy2022/): filed 2023-03-27; accession 0000950170-23-009854 (https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm)
- [FY 2021 MD&A](/company/TNGX/mda/fy2021/): filed 2022-03-28; accession 0000950170-22-004721 (https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm)

Back to /company/TNGX/